Saratov JOURNAL of Medical and Scientific Research


Cardiac remodeling in patients with chronic kidney disease

Year: 2019, volume 15 Issue: №2 Pages: 217-221
Heading: Internal Diseases Article type: Review
Authors: Sedov D.S., Rebrov А.Р.
Organization: Saratov State Medical University

The duration and quality of life of patients undergoing extracorporeal renal replacement therapy are largely dependent on concomitant diseases and conditions. Cardiovascular disease is a significant complication of chronic kidney disease and a major cause of death in patients undergoing hemodialysis. Cardiovascular remodeling is an independent predictor of the risk of cardiovascular events in patients with chronic kidney disease (CKD), including those in the dialysis stage. This paper analyzes the literature on left ventricular myocardial remodeling in the late predialysis stages of CKD and in patients receiving treatment with chronic hemodialysis.

2019_02_217-221.pdf306.44 KB

Atorvastatin effect on values of endotheli-al condition and acute inflammation in patients on program hemodialysis

Year: 2013, volume 9 Issue: №1 Pages: 39-42
Heading: Clinical Pharmacology Article type: Original article
Authors: Barsuk A.L, Vozova А.М., Malinok Е.V., Kuzin V.B., Lovtsova L.V., Okrut I.E.
Organization: N. Novgorod State Medical Academy

Objective: To study the effect of atorvastatin on the values of endothelial condition and acute inflammation in patients on program hemodialysis (PHD). Material and methods: The patients were divided into two groups: 28 PHD patients (main group) received atorvastatin, 20 mg once a day for 30 days, and 26 patients (control group) had PHD only. Endothelin 1-21 (ET) level and von Willebrand factor (vWF) activity were determined by enzyme immunoassay, nitric oxide (NO) levels — spectrophotometrically, C-reactive protein (CRP) — by immunoturbidimetric method, fibrinogen — by Clauss method. Results: After 30 days of observation, control patients were found to have NO and ET increase, as well as the reduced activity of vWF relative to initial data, while fibrinogen and CRP levels scarcely changed. The main group patients had similar changes of endothelial condition values, and their fibrinogen and CRP levels decreased. The correlation between the changes of ET and fibrinogen levels was recorded in the patients of the main group. Conclusion: 30-day administration of atorvastatin, 20 mg per day, lowers CRP and fibrinogen levels in PHD patients. It proves the applicability of statins in this group of patients in case of signs of inflammation.

2013-01_039-042.pdf293.75 KB